



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (5th September)

EXECUTIVE TEAM COMPLETES INTERNATIONAL MEETINGS – STRONG BUSINESS PROSPECTS IN EUROPE, ISRAEL AND CANADA

Key Points:

Key Points:

- ❖ **THC seeking exposure to the rapidly growing international marketplace**
- ❖ **International supply contracts under negotiation**
- ❖ **Canadian business acquisitions identified**
- ❖ **Further investment in CMDV**
- ❖ **Service and technology providers to the Canadian cannabis market engaged**
- ❖ **Engagement with potential European and Israeli partners**
- ❖ ***Medicinal Cannabis supply expected with MCMP rollout***

The Hydroponics Company (ASX: THC) (**THC** or **Company**) is pleased to provide the following update following recently completed international meetings held by its executive team in Europe, Israel and Canada.

In summary Israel, Canada and the European region continue to show strong growth in the supply and uptake of medicinal cannabis with both markets offering opportunities for growth for THC.

Alan Beasley, THC Chairman stated:

“Through the efforts of the THC management team visiting Europe Israel and Canada, the foundation has been laid for THC to access medicinal cannabis that has been in production and supplied for over ten years.”



The Hydroponics Company Limited
(ASX: THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime Street
Sydney NSW 2000

Europe and Israel

In Europe and Israel, the Company has identified several potential partners for a range of medical solutions.

Contract negotiations are underway with several these prospects.

The Company is well advanced in discussions with potential suppliers of medicinal product and is targeting *a medicinal cannabis product supply being available for dispensing in time for the Medicinal Cannabis Medicines Portal (MCMP)* rollout later this year. The MCMP is a collaborative approach between Prescribers, Pharmacists and Sponsors to help patients get timely access to appropriate medicinal cannabis treatment in-line with all applicable National and State/Territory based laws and requirements.

THC is a foundation Sponsor of the MCMP.

In Israel, THC engaged with companies that have been producing CBD/THC strains for over 10 years and are looking to work with THC in Australia to fast track THC's growing and manufacturing capabilities.

THC will advise the market as to future developments in the near term.

Canada

With international growth dynamics in mind, **THC confirms that it is making further investment in its Canadian subsidiary CMDV** to take advantage of this current and rapidly growing market. This investment is initially in increased personnel within CMDV, and several opportunities for acquisition in this marketplace have been identified.

The Company also confirms that it has engaged with a range of service and technology providers to the Canadian cannabis market with a view to business development within the Canadian market.

THC will update investors in the short to midterm as progress is made.

Australia

Within Australia the Company advises that it has made significant investments in its local manufacturing capability and expects that the *relative documentation necessary to allow for local manufacture and licensing should be in place later this year.*

The Company believes that the ability to invest in both developed and developing markets gives investors exposure to a range of market conditions allowing for investors to gain exposure to the rapidly growing international marketplace.

For further information, please contact:



Jarrold White
Company Secretary | Chief Financial Officer

The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney NSW 2000 Australia

P: +61 2 9251 7177



Michael Lovesey
Director Corporate Media Relations

MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mmercporate.com

About The Hydroponics Company

The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

Disclaimer Regarding Forward Looking Statements

This announcement contains forward-looking statements which are identified by italics words that involve risks and uncertainties. Indications of, and guidelines or outlook on, future earnings, distributions or financial position or performance and targets, estimates and assumptions in respect of production, prices, operating costs, results, capital expenditures, reserves and resources are also forward-looking statements. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions and estimates regarding future events and actions that, while considered reasonable as at the date of this announcement and are expected to take place, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the directors and management. We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are subject to various risk factors that could cause actual events or results to differ materially from the events or results estimated, expressed or anticipated in these statements.